» Articles » PMID: 33566263

Heterogeneity of Radiation Response in Mesenchymal Subtype Glioblastoma: Molecular Profiling and Reactive Oxygen Species Generation

Overview
Journal J Neurooncol
Publisher Springer
Date 2021 Feb 10
PMID 33566263
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Radiotherapy-induced tumor death remains critical in the successful first-line management of glioblastoma, whereas resistance to radiation serves as a major factor in disease progression. Mesenchymal shift has been identified as a driver in GBM recurrence, with gene expression associated with enhanced repair of macromolecular damage caused by radiation.

Methods: Using distinct mesenchymal subtype GBM cells lines, radiation response was assessed by clonogenic assay and orthotopic mouse tumor model. RNA-sequencing was performed in the setting of increasing radiation dosing while real-time assessment of ROS generation was achieved by the measurement of hydroxyl spin trap adducts via electron paramagnetic resonance.

Results: Radiation-induced cell death determined by clonogenic assay was significantly different at low dose (4-8 Gy) between the resistant U3035 cells and the sensitive U3020 cells. Similar trends were present in the in vivo NSG mouse model following radiation dosing on post-implantation day 7-10, with the rate of reduction in tumor bioluminescence reversing between the U3020 and U3035 cells after the third dose of radiation. Changes in gene expression following radiation determined by RNA-sequencing indicate both U3035 and U3020 cells demonstrate a shift toward more mesenchymal profiles, with concurrent shift away from pro-neural subtype gene expression in the U3020 cells that appeared to develop resistance to radiation in vivo. Persistence of ROS generated following radiation was greater in U3020 cells shown to be more sensitive to radiation.

Conclusions: Despite the same molecular classification, distinct GBM cell lines can demonstrate differential response to radiation and potential for mesenchymal shift associated with radiation resistance.

Citing Articles

Enhancing radiation-induced reactive oxygen species generation through mitochondrial transplantation in human glioblastoma.

Marshall K, Velayutham M, Khramtsov V, Mizener A, Cifarelli C Sci Rep. 2025; 15(1):7618.

PMID: 40038364 PMC: 11880374. DOI: 10.1038/s41598-025-91331-2.


Unveiling the Inflammatory Landscape of Recurrent Glioblastoma through Histological-Based Assessments.

Dadario N, Boyett D, Teasley D, Chabot P, Winans N, Argenziano M Cancers (Basel). 2024; 16(19).

PMID: 39409905 PMC: 11476027. DOI: 10.3390/cancers16193283.


The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma.

Wu Q, Berglund A, Macaulay R, Etame A Cells. 2024; 13(11.

PMID: 38891074 PMC: 11171993. DOI: 10.3390/cells13110942.


LncRNA MIR200CHG inhibits EMT in gastric cancer by stabilizing miR-200c from target-directed miRNA degradation.

Zhu Y, Huang C, Zhang C, Zhou Y, Zhao E, Zhang Y Nat Commun. 2023; 14(1):8141.

PMID: 38065939 PMC: 10709323. DOI: 10.1038/s41467-023-43974-w.


Conoidin A, a Covalent Inhibitor of Peroxiredoxin 2, Reduces Growth of Glioblastoma Cells by Triggering ROS Production.

Szeliga M, Rola R Cells. 2023; 12(15).

PMID: 37566013 PMC: 10417327. DOI: 10.3390/cells12151934.

References
1.
Al-Holou W, Hodges T, Everson R, Freeman J, Zhou S, Suki D . Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2019; 86(1):112-121. PMC: 8253299. DOI: 10.1093/neuros/nyz008. View

2.
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B . Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318(23):2306-2316. PMC: 5820703. DOI: 10.1001/jama.2017.18718. View

3.
Cloughesy T, Mochizuki A, Orpilla J, Hugo W, Lee A, Davidson T . Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019; 25(3):477-486. PMC: 6408961. DOI: 10.1038/s41591-018-0337-7. View

4.
Sun M, Oh T, Ivan M, Clark A, Safaee M, Sayegh E . Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. J Neurosurg. 2015; 122(5):1144-50. DOI: 10.3171/2014.9.JNS14193. View

5.
Niyazi M, Brada M, Chalmers A, Combs S, Erridge S, Fiorentino A . ESTRO-ACROP guideline "target delineation of glioblastomas". Radiother Oncol. 2016; 118(1):35-42. DOI: 10.1016/j.radonc.2015.12.003. View